There are 413 resources available
215P - Impact of Her2 Low on Survival in Patients Treated with Standard Therapies in Advanced Breast Cancer
Presenter: Stephanie Graff
Session: Poster viewing and lunch
216P - Sacituzumab govitecan in metastatic triple negative breast cancer: efficacy -with a focus on brain metastases- and toxicity in a real-world cohort
Presenter: Delphine Loirat
Session: Poster viewing and lunch
217P - Incidence and outcome of brain and/or leptomeningeal metastatic disease in HER2-low breast cancer in the French ESME cohort.
Presenter: Jean-Sebastien Frenel
Session: Poster viewing and lunch
218P - Characteristics and outcomes of HER2-low (H-Low) and HER2-zero (H-0) advanced breast cancer (ABC) patients (pts) from GEICAM/2014-03 (RegistEM) registry
Presenter: Isabel Alvarez Lopez
Session: Poster viewing and lunch
219P - Chemotherapy use and survival outcomes for patients diagnosed with metastatic hormone receptor-positive HER2-negative breast cancer, results from the Dutch SONABRE Registry
Presenter: Sandra Geurts
Session: Poster viewing and lunch
220P - Oral Selective Estrogen Receptor Degraders for metastatic hormone receptor-positive, HER2 negative breast cancer according to ESR1 mutation: a systematic review and meta-analysis of randomized control trials.
Presenter: Roberto Gabriel Santiago Novello
Session: Poster viewing and lunch
221P - HERmione, a crossed-view survey about patients living with metastatic HER2-positive Breast Cancer
Presenter: Laure Gueroult-Accolas
Session: Poster viewing and lunch
222P - Real-world clinical outcomes among patients (pts) with metastatic/advanced triple-negative breast cancer (mTNBC) in the United Kingdom (UK) and Germany (GER)
Presenter: Peter A. Fasching
Session: Poster viewing and lunch
223P - Real-World Effectiveness of Palbociclib (Pal) Plus an Aromatase Inhibitor (AI) vs AI Alone in Patients Who Have Metastatic Breast Cancer (mBC) With Lung or Liver Metastases
Presenter: Adam Brufsky
Session: Poster viewing and lunch
224P - Clinical features and outcomes in HER2+ mBC patients treated with Trastuzumab deruxtecan: a subgroup analysis of the De-REAL study
Presenter: Andrea Botticelli
Session: Poster viewing and lunch